April Journal-2009.p65 - Association of Biotechnology and Pharmacy
April Journal-2009.p65 - Association of Biotechnology and Pharmacy
April Journal-2009.p65 - Association of Biotechnology and Pharmacy
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Current Trends in <strong>Biotechnology</strong> <strong>and</strong> <strong>Pharmacy</strong><br />
Vol. 3 (2) 181-187, <strong>April</strong> 2009. ISSN 0973-8916<br />
each genotype to develop disease. Differences<br />
in genotype frequency distribution between<br />
disease <strong>and</strong> control groups was done using 2*2<br />
χ2 <strong>and</strong> χ2 test for heterogeneity.<br />
Results <strong>and</strong> Discussion<br />
The cytochrome P450 (CYP) catalyzes<br />
the metabolism <strong>of</strong> numerous exogenous <strong>and</strong><br />
endogenous molecules. CYP3A5 was found to<br />
be more efficient in activating aflotoxin B1 to<br />
carcinogenic form (9). CYP3A5 was considered<br />
as a c<strong>and</strong>idate gene for prostate cancer as the<br />
expression was observed in both normal as well<br />
as in tumor tissue, whereas CYP3A4 expression<br />
was limited to normal prostate tissue. The<br />
hypothesis that prostate cancer risk might be<br />
associated with CYP3A5 genotype had been<br />
strengthened by the report <strong>of</strong> linkage<br />
183<br />
disequilibrium between CYP3A5 <strong>and</strong> CYP3A4<br />
alleles (10). The proportion <strong>of</strong> CYP3A4*1B <strong>and</strong><br />
CYP3A5*1 alleles was found to be increased in<br />
liver, gastric <strong>and</strong> colorectal cancer patients (11)<br />
<strong>and</strong> these findings were in accordance with other<br />
studies from Caucasian population (12).<br />
In the present study, the frequency <strong>of</strong><br />
heterozygotes for CYP3A5*1 (1/3) was<br />
significantly increased in breast cancer (53.0%)<br />
when compared to controls (41.4%) with<br />
corresponding increase in 3A5*1 allele frequency<br />
(Table 1). The study group showed deviation from<br />
Hardy-Weinberg equilibrium but not controls<br />
(÷2=0.58) indicating selective forces operating in<br />
disease group (÷2=5.09*) (Table 1). The<br />
frequency <strong>of</strong> CYP3A5*3 allele was found to be<br />
similar in both leukemia (CML, AML) group <strong>and</strong><br />
controls (7). Nogal et al (13) had reported that<br />
Table 1. CYP3A5*3 polymorphism with respect to breast cancer <strong>and</strong> epidemiological parameters<br />
Parameters 1/1 1/3 3/3 Allele<br />
Frequency<br />
n % n % n % 1 3<br />
Disease (249) 25 10.0 132 53.0 92 37.0 0.37 0.63<br />
Controls (249) 28 11.2 103 41.4 118 47.4 0.32 0.68<br />
Menopausal Status<br />
Premenopausal (124) 10 8.1 72 58.1 42 33.9 0.37 0.63<br />
Postmenopausal (125) 15 12.0 60 48.0 50 40.0 0.36 0.64<br />
Familial History<br />
Familial (74) 2 2.7 32 43.2 40 54.1 0.24 0.76<br />
Non-Familial (176) 2 1.1 70 39.8 104 59.1 0.21 0.79<br />
BMI<br />
30 (45) 4 8.9 21 46.7 20 44.5 0.32 0.68<br />
Occupation<br />
Housewives (173) 2 1.2 66 38.2 105 60.7 0.20 0.80<br />
Agriculture (27) 0 0 15 55.6 12 44.4 0.28 0.72<br />
White-Collar Jobs (43) 2 4.7 17 39.5 24 55.8 0.24 0.76<br />
Others (7) 0 0 4 57.1 3 42.9 0.21 0.79<br />
CYP3A5*3 <strong>and</strong> CYP3A5*6 Polymorphisms <strong>and</strong> Breast Cancer